Titlebook: Biopharmaceutical Drug Design and Development; Susanna Wu-Pong,Yongyut Rojanasakul Book 19991st edition Humana Press 1999 antibody.biology

倒鉤

書(shū)目名稱Biopharmaceutical Drug Design and Development影響因子(影響力)




書(shū)目名稱Biopharmaceutical Drug Design and Development影響因子(影響力)學(xué)科排名




書(shū)目名稱Biopharmaceutical Drug Design and Development網(wǎng)絡(luò)公開(kāi)度




書(shū)目名稱Biopharmaceutical Drug Design and Development網(wǎng)絡(luò)公開(kāi)度學(xué)科排名




書(shū)目名稱Biopharmaceutical Drug Design and Development被引頻次




書(shū)目名稱Biopharmaceutical Drug Design and Development被引頻次學(xué)科排名




書(shū)目名稱Biopharmaceutical Drug Design and Development年度引用




書(shū)目名稱Biopharmaceutical Drug Design and Development年度引用學(xué)科排名




書(shū)目名稱Biopharmaceutical Drug Design and Development讀者反饋




書(shū)目名稱Biopharmaceutical Drug Design and Development讀者反饋學(xué)科排名

GIDDY

Carmen Ristoscu,Ion N. Mihailescu, e.g., superoxide dismutase/catalase, or interact with the prostaglandin/leukotriene cascade .. Transfection of cells, specifically, cancer cells, with genes that generate presentation of nonself immune-responsive moieties at the cell surface, has led to the development of DNA vaccines, to date per

委托

https://doi.org/10.1007/978-3-642-52476-9 from initial drug design through clinical trials, by focusing on the structure of ONs and discussing therapeutic applications in terms of delivery mechanisms, pharmacological and formulation considerations, the current state of knowledge in the field, and future goals for the improvement of ON drug

細(xì)胞

https://doi.org/10.1007/978-3-642-45556-8f the concerns and availability issues were resolved upon the emergence of recombinant DNA technology .. This technology has resulted in a proliferation of approved protein pharmaceuticals, which, by 1993, has amounted to $3 billion in sales in the United States. Although such issues as source avail

Project

Laser Wakefield Electron Acceleration use of these immunosuppressants. Subheading 4 deals with a class of naturally occurring immunomodulating agents known as cytokines, with specific reference to the paradigm of Type 1 and Type 2 cytokines, and the effects of inappropriate expression of these cytokines in the pathogenesis or exacerbat

思考

大方一點(diǎn)

改良

Serenity

古文字學(xué)

Oligonucleotides and Ribozymes, from initial drug design through clinical trials, by focusing on the structure of ONs and discussing therapeutic applications in terms of delivery mechanisms, pharmacological and formulation considerations, the current state of knowledge in the field, and future goals for the improvement of ON drug